A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa

Antimicrob Agents Chemother. 1992 May;36(5):1057-61. doi: 10.1128/AAC.36.5.1057.

Abstract

An enoxacin-resistant Pseudomonas aeruginosa mutant (G49) isolated during patient therapy was characterized in detail. The G49 mutant was cross resistant to several classes of antibiotics including quinolones, beta-lactams, chloramphenicol, and tetracycline, but not imipenem or aminoglycosides. Compared with its paired pretherapy isolate G48, this mutant had several alterations in outer membrane proteins including a complete loss of the major porin protein OprF and a substantially altered lipopolysaccharide profile. Revertants were selected at a frequency of approximately 1% after enrichment for OprF+ cells on low-salt proteose peptone no. 2 medium. Ninety-seven of these OprF+ revertants were as susceptible to carbenicillin and norfloxacin as the pretherapy isolate. One of these revertants was characterized in more detail and shown to be indistinguishable in all properties from the pretherapy isolate. It is proposed that the multiple-antibiotic-resistance (Mar) phenotype of this mutant resulted from a single pleiotropic mutation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacterial Outer Membrane Proteins / analysis
  • Drug Resistance, Microbial
  • Electrophoresis, Polyacrylamide Gel
  • Enoxacin / pharmacology*
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / genetics
  • beta-Lactamases / analysis

Substances

  • Anti-Bacterial Agents
  • Bacterial Outer Membrane Proteins
  • Enoxacin
  • beta-Lactamases